HOME › DRUGS › REPOTRECTINIB
ACTIVE SUBSTANCE / INN

REPOTRECTINIB

Brand name(s): Augtyro, AUGTYRO
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
Carcinoma, Non-Small-Cell Lung;Cancer
NDA218213
ACTIVE SUBSTANCE
Repotrectinib
REGULATORS
FDA · EMA
SPONSORS / MAH
BRISTOL, Bristol-Myers Squibb Pharma EEIG
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
AUGTYRONDA218213BRISTOLPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
AugtyroBristol-Myers Squibb Pharma EEIGAuthorised13/01/2025Carcinoma, Non-Small-Cell Lung;Cancer

FULL INTELLIGENCE ON REPOTRECTINIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →